Veru (NASDAQ:VERU) Releases Earnings Results, Beats Estimates By $0.01 EPS

Veru (NASDAQ:VERU) announced its quarterly earnings results on Monday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01, Zacks reports. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%.

Veru Stock Up 8.7 %

NASDAQ:VERU traded up $0.06 during trading hours on Monday, reaching $0.79. 2,370,238 shares of the company’s stock were exchanged, compared to its average volume of 1,602,859. Veru has a 1-year low of $0.36 and a 1-year high of $1.92. The firm has a market capitalization of $114.97 million, a price-to-earnings ratio of -1.66 and a beta of -0.50. The company has a 50-day moving average of $0.76 and a 200 day moving average of $0.82.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reiterated an “outperform” rating and set a $5.00 target price on shares of Veru in a research report on Tuesday, November 5th.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.